August 31, 2015
New York-based Progyny hopes to improve the high failure rate of in vitro fertilization with its Early Embryo Viability Assessment (EEVA) test, which uses imaging technology to track and evaluate embryo development.
[image courtesy of PROGYNY]
Correction: An earlier version of this slideshow incorrectly identified the company as Auxogyn. Auxogyn merged with Fertility Authority in April 2015 to form Progyny.
You May Also Like